etofibrate has been researched along with niacin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ojeda, G; Portolés, A; Portolés, MP; Rojo, JM | 1 |
| Altmayer, P; Garrett, ER | 1 |
| Chasseaud, LF; Schatton, W; Taylor, T; Waller, AR | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Steger, W | 1 |
| Sinzinger, H | 1 |
| Caramelli, B; Mansur, AP; Ramires, JA; Serrano, CV; Spósito, AC | 1 |
| Coelho, OR; Mansur, AP; Maranhão, RC; Ramires, JA; Rodrigues-Sobrinho, CR; Sposito, AC | 1 |
1 review(s) available for etofibrate and niacin
| Article | Year |
|---|---|
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
4 trial(s) available for etofibrate and niacin
| Article | Year |
|---|---|
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hyperlipoproteinemias; Male; Middle Aged; Niacin; Nicotinic Acids; Triglycerides | 1980 |
Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Delayed-Action Preparations; Drug Administration Schedule; Drug Synergism; Female; Humans; Lipids; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome | 1999 |
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Topics: Analysis of Variance; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoprotein(a); Male; Middle Aged; Niacin; Statistics, Nonparametric; Triglycerides | 2001 |
3 other study(ies) available for etofibrate and niacin
| Article | Year |
|---|---|
Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes.
Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Niacin; Thiophenes; Ticlopidine | 1985 |
Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
Topics: Animals; Clofibrate; Clofibric Acid; Dogs; Esters; Half-Life; Hypolipidemic Agents; Injections, Intravenous; Kinetics; Male; Niacin; Solubility; Solvents; Time Factors | 1985 |
Bioavailability studies of etofibrate in rhesus monkeys.
Topics: Animals; Biological Availability; Clofibrate; Clofibric Acid; Drug Interactions; Female; Half-Life; Hypolipidemic Agents; Intestinal Absorption; Macaca mulatta; Niacin; Time Factors | 1985 |